Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTXGet Free Report) have received a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $8.30.

CGTX has been the subject of several research analyst reports. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. Chardan Capital restated a “buy” rating and set a $11.00 price objective on shares of Cognition Therapeutics in a research report on Thursday, December 19th. Finally, HC Wainwright boosted their target price on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th.

Read Our Latest Analysis on CGTX

Cognition Therapeutics Price Performance

Shares of CGTX opened at $0.61 on Tuesday. The firm has a market cap of $25.51 million, a P/E ratio of -0.63 and a beta of 1.26. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95. The company has a 50 day simple moving average of $0.48 and a two-hundred day simple moving average of $0.91.

Institutional Trading of Cognition Therapeutics

Several hedge funds have recently made changes to their positions in the business. CM Management LLC increased its stake in Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after acquiring an additional 25,000 shares during the last quarter. Sigma Planning Corp boosted its holdings in shares of Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares during the period. Mercer Global Advisors Inc. ADV increased its position in shares of Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Cognition Therapeutics during the 3rd quarter valued at $27,000. 43.35% of the stock is currently owned by hedge funds and other institutional investors.

Cognition Therapeutics Company Profile

(Get Free Report

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.

Further Reading

Analyst Recommendations for Cognition Therapeutics (NASDAQ:CGTX)

Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.